Αποτελέσματα Αναζήτησης
Adult: Replacement of endogenous GH in adults with growth hormone deficiency. Pediatric Patients: Treatment of children with growth failure due to growth hormone deficiency (GHD), idiopathic short stature (ISS), Turner syndrome (TS), and chronic kidney disease (CKD) up to the time of renal transplantation.
One vial of powder contains nominally: 500 IU* human coagulation factor VIII** (FVIII). 1200 IU*** human von Willebrand factor** (VWF). After reconstitution with the 10 ml water for injections provided, the solution contains 50 IU/ml of FVIII and 120 IU/ml of VWF.
Cefuroxime for Injection, USP contains approximately 54.2 mg (2.4 mEq) of sodium per gram of cefuroxime activity. Cefuroxime for Injection, USP in sterile crystalline form is supplied in vials equivalent to 750 mg or 1.5 g of cefuroxime as cefuroxime sodium.
Norditropin ® (somatropin) injection is indicated for the treatment of pediatric patients with: growth failure due to inadequate secretion of endogenous growth hormone (GH) short stature associated with Noonan syndrome,
Voncento 1000 IU FVIII / 2400 IU VWF powder and solvent for solution for injection/infusion Powder (1000 IU/2400 IU) in a vial (type I glass), with a stopper (rubber) a disc (plastic) and a cap (aluminium).
30 Ιαν 2024 · The patients received 1 pre-operative injection of 80 IU/kg on the day of surgery, and post-operatively, injections of 40 IU/kg. A pre-operative dose of 80 IU/kg Refixia was effective and no patients required additional doses on the day of surgery.
ADVATE 250 IU, 500 IU, 1000 IU, 1500 IU, 2000 IU and 3000 IU powder and solvent for solution for injection 5 ml solvent - Baxject II - Summary of Product Characteristics (SmPC) by Takeda UK Ltd.
